Modification No. 22 to Contract No. IIllSN272201300017C Increasing Estimated Cost for Option 10
This contract modification is between the parties to Contract No. IIllSN272201300017C. It increases the estimated cost of the contract to $43,034,602 to cover additional Mad and Dosing studies with more patients, as described in Option 10. The modification allocates $3,557,707 for these studies, with payments to be made from specified PRISM/NBS Line Item Numbers. The period of performance for these changes is from August 10, 2016, to September 30, 2022.
Exhibit 10.3
John E. Outen - S Digitally signed by John E. Outen - S Date: 2018.09.12 09:45:25 - 04'00'
SPECIAL PROVISIONS Contract No. IIllSN272201300017C Modification No. 22 Page 2 of2 Beginning with the effective date of this modification, ARTICLE B.2. ESTIMATED COST - OPTION AND ARTICLE G.3 INVOICE SUBMISSION /CONTRACT FINANCING REQUEST IS REVISED ARTICLE B.2. ESTIMATED COST - OPTION 10 is revised to incorporate changes (a, and b) with changes in the Option 10 table below: a. The estimated cost of this contract is increased to $43,034,602 with the addition of Mad and Dosing studies with additional patients as described in Option 10 for $3,557 , 707. b. Payments from the additional funds may be made from the following PRISM/NBS Line Item Numbers as follows: PRISM/NBS Line Item No. Description PRISM/NBS Line Item Period of Performance Funded Amount 20 Mad Studies for Yellow Fever and Marburg program changes under Option 10 08/10/2016 - 09/30/2022 $3,557,707 END OF MODIFICATION 22 OF IIllSN272201300017C
